Stock EWLS EDWARDS LIFESCIENCES CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Edwards Lifesciences Corporation Wiener Boerse

Equities

EWLS

US28176E1082

Real-time Estimate Tradegate
Other stock markets
 03:57:45 2024-05-24 am EDT 		5-day change 1st Jan Change
81.54 EUR -0.70% Intraday chart for Edwards Lifesciences Corporation -1.18% +18.36%
May. 23 Some of the biggest splits in Corporate America RE
May. 22 Citigroup Upgrades Edwards Lifesciences to Buy From Neutral, Adjusts Price Target to $105 From $98 MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 33.08 times its estimated earnings per share for the ongoing year.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is highly valued given the cash flows generated by its activity.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

1st Jan change Capi. Investor Rating ESG Refinitiv
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+18.36% 52.7B -
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+10.22% 223B
B
DANAHER CORPORATION Stock Danaher Corporation
+12.99% 194B
B-
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+18.09% 141B
B-
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+28.66% 109B
A-
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
+1.63% 64.85B
A-
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
+6.68% 51.77B
B+
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
+8.29% 44.12B
A
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+2.60% 36.21B -
RESMED, INC. Stock ResMed, Inc.
+23.00% 31.08B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. EW Stock
  4. EWLS Stock
  5. Ratings Edwards Lifesciences Corporation